1. Home
  2. KSS vs MESO Comparison

KSS vs MESO Comparison

Compare KSS & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kohl's Corporation

KSS

Kohl's Corporation

HOLD

Current Price

$17.67

Market Cap

2.1B

ML Signal

HOLD

Logo Mesoblast Limited

MESO

Mesoblast Limited

HOLD

Current Price

$17.19

Market Cap

2.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KSS
MESO
Founded
1962
2004
Country
United States
Australia
Employees
N/A
N/A
Industry
Department/Specialty Retail Stores
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.1B
IPO Year
1995
2005

Fundamental Metrics

Financial Performance
Metric
KSS
MESO
Price
$17.67
$17.19
Analyst Decision
Sell
Strong Buy
Analyst Count
15
1
Target Price
$15.31
N/A
AVG Volume (30 Days)
3.0M
176.4K
Earning Date
05-28-2026
02-26-2026
Dividend Yield
3.58%
N/A
EPS Growth
142.86
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$629.74
Revenue Next Year
$0.21
$30.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.38
$12.66
52 Week High
$25.22
$21.50

Technical Indicators

Market Signals
Indicator
KSS
MESO
Relative Strength Index (RSI) 45.61 55.82
Support Level $17.06 $16.67
Resistance Level $20.09 $17.10
Average True Range (ATR) 0.84 0.36
MACD -0.24 0.06
Stochastic Oscillator 32.46 55.25

Price Performance

Historical Comparison
KSS
MESO

About KSS Kohl's Corporation

Kohl's is the second-largest traditional US department store company by sales. It has about 1,150 stores in 49 states and offers moderately priced private-label (31% of 2025 sales) and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most (about 80%) of its stores are in strip centers. Kohl's also has a large digital sales operation (29% of 2025 sales). Women's apparel is the retailer's largest category, having generated 24% of its 2025 sales. Kohl's is headquartered in Menomonee Falls, Wisconsin, and was founded in 1962.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: